The Janssen Pharmaceutical Companies of Johnson & Johnson disclosed its exit from the investigational RSV adult vaccine program.
The Janssen Pharmaceutical Companies of Johnson & Johnson disclosed that following a review of its portfolio to prioritize the most transformational assets for ongoing investment, and an assessment of the respiratory syncytial virus (RSV) vaccine landscape, the Company will exit its investigational RSV adult vaccine program and discontinue its Phase III EVERGREEN study.
The decision to discontinue the Company’s RSV adult vaccine program is part of a broader effort to make strategic choices for its pipeline and research and development (R&D) investments to focus on medicines with the greatest potential benefit to patients. The Company remains committed to investing in internal discovery, development and external innovation across its Therapeutic Areas.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.